Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments
- DOI
- 10.1177/11795735241260563
- Published
- 2024-09-13
- Container
- Journal of Central Nervous System Disease
- Publisher
- SAGE Publications
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1177/11795735241260563,
title = {Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments},
author = {Erwan Muros-Le Rouzic and Yanic Heer and Sean Yiu and Viola Tozzi and Stefan Braune and Philip van Hövell and Arnfin Bergmann and Corrado Bernasconi and Fabian Model and Licinio Craveiro and Unknown},
year = {2024},
journal = {Journal of Central Nervous System Disease},
doi = {10.1177/11795735241260563},
url = {https://doi.org/10.1177/11795735241260563}
}RIS
TY - JOUR TI - Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments AU - Erwan Muros-Le Rouzic AU - Yanic Heer AU - Sean Yiu AU - Viola Tozzi AU - Stefan Braune AU - Philip van Hövell AU - Arnfin Bergmann AU - Corrado Bernasconi AU - Fabian Model AU - Licinio Craveiro AU - Unknown PY - 2024 JO - Journal of Central Nervous System Disease DO - 10.1177/11795735241260563 UR - https://doi.org/10.1177/11795735241260563 ER -
APA
Rouzic, E. M., Heer, Y., Yiu, S., Tozzi, V., Braune, S., Hövell, P. V., Bergmann, A., Bernasconi, C., Model, F., Craveiro, L., & Unknown (2024). Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments. Journal of Central Nervous System Disease. https://doi.org/10.1177/11795735241260563
Source records
- crossref · retrieved 2026-11-10T12:41:27.394Z